Sparks commentary

Healthcare

Sparks

Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan
Published by Arron Aatkar, PhD

Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the region, and the subsequent regulatory submission process for the candidate in metastatic colorectal cancer. According to Solasia, the Phase II trial is intended to take place across 2025 and 2026, followed by a Phase III trial and regulatory submission between 2027 and 2029. Isofol will support the programme and ensure alignment with the clinical development in other geographical regions.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free